News

News from Chiesi

2023-06-29T15:17:17+02:00

Chiesi Global Rare Diseases and Protalix BioTherapeutics Announce European Commission Authorization of PRX-102 (pegunigalsidase alfa) for the Treatment of Fabry Disease

News from Chiesi2023-06-29T15:17:17+02:00

News from Sanofi

2023-06-29T14:57:10+02:00

Sanofi dedicated their Fabry Awareness Month Campaign to highlighting the psychological impact of Fabry.

News from Sanofi2023-06-29T14:57:10+02:00
Go to Top